1GDA.F KEMPHARM INC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
10.55 EUR
Close of Nov 11, 2026
6.85 12.85
Market cap
EUR 628M
P/E
9.6x
P/B
2.98x
ROE
36.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1GDA.F undervalued?

Graham number
Price10.55
Graham value9.37
Premium12.6%

1GDA.F trades 12.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KEMPHARM INC. DL-0001 fundamental analysis

No fundamental analysis for KEMPHARM INC. DL-0001 yet.

KEMPHARM INC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KEMPHARM INC. DL-0001

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol,…

Full company profile